IONIS PHARMACEUTICALS INC — Capital/Financing Update 2012

Jan 4, 2012

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934*

Date of report (Date of earliest event reported): January 4, 2012

*ISIS PHARMACEUTICALS, INC.*

(Exact Name of Registrant as Specified in Charter)

*Delaware*

(State or Other Jurisdiction of Incorporation)

000-19125	33-0336973
(Commission File No.)	(IRS Employer Identification No.)

*2855 Gazelle Court*

*Carlsbad, CA 92010*

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (760) 931-9200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\105728\12-2023-1\task5029479\2023-1-ba.htm',USER='105728',CD='Jan 4 07:38 2012'

Item 1.01. Entry into a Material Definitive Agreement.

On January 4, 2012, Isis Pharmaceuticals, Inc. (“Isis”) and Biogen Idec announced that they have entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize Isis’ antisense investigational drug, ISIS-SMNRx, for the treatment of spinal muscular atrophy.

Isis and Biogen Idec filed a press release describing this transaction. A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated January 4, 2012.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\105728\12-2023-1\task5029479\2023-1-ba.htm',USER='105728',CD='Jan 4 07:38 2012'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/s/ B. Lynne Parshall
B. LYNNE PARSHALL
Chief Operating Officer,
Chief Financial Officer and Director

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\105728\12-2023-1\task5029479\2023-1-ba.htm',USER='105728',CD='Jan 4 07:38 2012'

INDEX TO EXHIBITS

99.1 Press Release dated January 4, 2012.

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\105728\12-2023-1\task5029479\2023-1-ba.htm',USER='105728',CD='Jan 4 07:38 2012'